Silicon Valley Capital Partners Lowers Stock Position in Novo Nordisk A/S (NYSE:NVO)

Silicon Valley Capital Partners cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 52.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 738 shares of the company’s stock after selling 802 shares during the period. Silicon Valley Capital Partners’ holdings in Novo Nordisk A/S were worth $64,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S in the 3rd quarter worth $28,000. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S in the 3rd quarter worth $42,000. Albion Financial Group UT lifted its holdings in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares in the last quarter. Sound Income Strategies LLC lifted its holdings in Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after buying an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC acquired a new position in Novo Nordisk A/S in the 4th quarter worth $46,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $86.39 on Monday. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The stock has a market cap of $387.66 billion, a price-to-earnings ratio of 26.26, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45. The company has a 50-day moving average price of $91.46 and a two-hundred day moving average price of $111.36.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts forecast that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is currently 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.